|
See related Survanta intratracheal susp information |
|
|
|
Manufacturer |
Abbott |
|
Distributor |
Zuellig |
|
Contents |
Beractant (equiv to phospholipids 25 mg/mL, triglycerides 0.5-1.75 mg/mL, free fatty acids 1.4-3.5 mg/mL, protein <1 mg/mL) |
|
Indications |
Prevention & treatment of resp distress syndrome (RDS) in premature infants. |
|
Dosage |
100 mg of phospholipids/kg birth wt (4 mL/kg birth wt). |
|
Special Precautions |
Infants <600 g birth wt. For intratracheal use only. |
|
Adverse Drug Reactions |
Transient bradycardia. O2 desaturation.
View ADR Monitoring Form |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Survanta intratracheal suspension |
|
Survanta (vial) 25 mg/1 mL x 8 mL |
|
|
|
Manufacturer: |
Abbott |
|
Distributor: |
Zuellig |
|
 |
|
|
|
